Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients

International Journal of Clinical Pharmacology and Therapeutics

Volumn 41, Issue 10, 2003, Pages 470-476

  Glander, Petra ^a   Hambach, P ^a   Braun, K P ^a   Fritsche, L ^a   Waiser, J ^a   Mai, I ^a   Neumayer, H H ^a   Budde, K ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

IMP dehydrogenase; Kidney transplantation; Mycophenolate mofetil; Pharmacodynamics; Pharmacokinetics

Indexed keywords

DRUG METABOLITE; IMMUNOSUPPRESSIVE AGENT; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD DONOR; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG MONITORING; DRUG RESPONSE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL TOXICITY; HEMODIALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LONG TERM CARE; MAINTENANCE THERAPY; MALE; MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PHARMACODYNAMICS; PREOPERATIVE PERIOD; RECIPIENT; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TARGET CELL; TREATMENT OUTCOME; VOLUNTEER;

EID: 0141996252     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP41470     Document Type: Article

References (24)

1. Albrecht W, Storck M, Pfetsch E, Martin W, Abendroth D 2000 Development and application of a high-performance liquid chromatography based assay for determination of the activity of inosine 5′-monophosphate dehydrogenase in whole blood and isolated mononuclear cells. Ther Drug Monit 22: 283-294
2. Brunet M, Martorell J, Oppenheimer F, Vilardell J, Millan O, Carrillo M, Rojo I, Corbella J 2000 Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil. Transpl Int 13: 301S-305S
3. Bullingham RES, Nicholls AJ, Kamm BR 1998 Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34: 429-455
4. Cattaneo D, Gaspari F, Ferrari S, Stucchi N, Del Priore L, Perico N, Gotti E, Remuzzi G 2001 Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin Transplant 15: 402-409
5. Eugui EM, Mirkovich A, Allison AC 1991 Lymphocyte-selective antiproliferative and immunosuppressive activity of mycophenolic acid and its morpholinoethyl ester (RS-61443) in rodents. Transplant Proc 23: 15-18
6. Fairbanks LD, Bofill M, Ruckemann K, Simmonds HA 1995 Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J Biol Chem 270: 29682-29689
7. van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, Hene RJ, Verpooten GA Navarro MT, Hale MD, Nicholls AJ 1999 A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 68: 261-266
8. Glander P, Braun KP, Hambach P, Bauer S, Mai I, Roots I, Waiser J, Fritsche L, Neumayer HH, Budde K 2001 Non-radioactive determination of inosine 5′-monophosphate dehydrogenase (IMPDH) in peripheral mononuclear cells. Clin Biochem 34: 543-549
9. Hale MD, Nicholls AJ, Bullingham RE, Hene R, Hoitsma A, Squifflet JP, Weimar W, Vanrenterghem Y, Van de Woude FJ, Verpooten GA 1998 The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 64: 672-683
10. Kaplan B, Meier-Kriesche HU, Friedman G, Mulgaonkar S, Gruber S, Korecka M, Brayman KL, Shaw LM 1999 The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol 39: 715-720
11. Langman LJ, LeGatt DF, Halloren PF, Yatscoff RW 1996a Pharmacodymnic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. Transplantation 62: 666-672
12. Langman LJ, Shapiro AM, Lakey JRT, LeGatt DF, Kneteman NM, Yatscoff RW 1996b Pharmacodymnic assessment of mycophenolic acid-induced immunosuppression by measurement of IMPDH activity in a canine model. Transplantation 61: 87-92
13. Millan O, Oppenheimer F, Brunet M, Vilardell J, Rojo I, Vives J, Martorell J 2000 Assessment of mycophenolic acid-induced immunosuppression: a new approach. Clinical Chemistry 46: 1376-1383
14. Montero C, Duley JA, Fairbanks LD, McBride MB, Micheli V, Cant AJ, Morgan G 1995 Demonstration of induction of erythrocyte inosine 5′monophosphate dehydrogenase activity in ribavirin-treated patients using a high-performance liquid chromatography-linked method. Clin Chim Acta 238: 169-178
15. Morgera S, Neumayer HH, Fritsche L, Kuchinke S, Lampe D, Ahnert V, Bauer S, Mai I, Budde K 1998 Pharmacokinetics of mycophenolate mofetil in renal transplant recipients on peritoneal dialysis. Int J Clin Pharmacol Ther 36: 159-163
16. Mourad M, Malaise J, Chaib Eddour D, De Meyer M, König J, Schepersch R, Squiffelt JP, Wallemacq P 2001 Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clinical Chemistry 47: 88-94
17. Nowak I, Shaw LM 1995 Mycophenolic acid binding to human serum-albumin: Characterization and relation to pharmacodynamics. Clin Chem 41: 1011-1017
18. Sanquer S, Breil M, Baron C, Dhamane SD, Astier A, Lang P 1999 Induction of inosine 5′monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil. Clin Pharmacol Ther 65: 640-648
19. Shaw LM, Nicholls AJ, Hale M, Armstrong VW, Oellerich M, Yatscoff R, Morris RE, Holt DW, Venkataramanan R, Haley J, Halloran P, Ettenger R, Keown P, Morris RG 1998 Therapeutic drug monitoring of mycophenolic acid. A consensus panel report. Clin Biochem 31: 317-322
20. Shaw LM, Kaplan B, DeNofrio D, Korecka M, Brayman KL 2000 Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. Ther Drug Monit 22: 14-19
21. Storck M, Abendroth D, Albrecht W, Sollinger HW 1999 IMPDH activity in whole blood and isolated blood cell fraction for monitoring of CellCept-mediated immunosuppression. Transplant Proc 31: 1115-1116
22. Tomlanovich SJ (corr Addr) US Renal Transplant Mycophenolate Mofetil Study Group 1999 Mycophenolate mofetil in cadaveric renal transplantation. Am J Kidney Dis 34: 296-303
23. Vanrenterghem Y (addr Corr) European Mycophenolate Mofetil Cooperative Study Group 1999 Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. Transplantation 68: 391-396
24. Weber G 1991 IMP dehydrogenase and GTP as targets in human leukemia treatment. Adv Exp Med Biol 309: 287-292